JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gross, G. J.
Right arrow Articles by Daemmgen, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gross, G. J.
Right arrow Articles by Daemmgen, J. W.

Beneficial effects of two specific bradycardic agents AQ-A39 (falipamil) and AQ-AH 208 on reversible myocardial reperfusion damage in anesthetized dogs

GJ Gross and JW Daemmgen

The effects of 2 specific bradycardic agents, AQ-A39 [5,6-dimethoxy-2- [3-([alpha-(3,4-dimethoxy)phenylethyl]methyl-amino) propyl]phthalimidine hydrochloride] and AQ-AH 208 [3,4-dihydro-6,7- dimethoxy-2-]3-[(2-[3, 4-dimethoxy-phenyl)-ethyl]-aminoethyl]propyl[- 1(2H)isoquinone] were evaluated for their effects on subendocardial segment shortening (% SS) as measured by sonomicrometry and regional myocardial blood flow (radioactive microspheres) in anesthetized dogs subjected to a 15 min left anterior descending coronary occlusion followed by 3 hr of reperfusion. AQ-A39 (2.5-mg/kg bolus + 100 micrograms/kg/min i.v.) and AQ-AH 208 (0.5-mg/kg bolus + 25 micrograms/kg/min i.v.) were administered 15 min before coronary occlusion, during occlusion and throughout reperfusion. Both agents produced equivalent reductions in heart rate (24%) and the heart rate- systolic pressure product (27%) without any other significant hemodynamic changes. Collateral blood flow to the ischemic area was not different between the drug-treated and control groups. During coronary occlusion and throughout reperfusion, however, % SS was significantly (P less than .05) improved by both agents in the ischemic-reperfused area as compared to a control group. Thus, the beneficial actions of AQ- A39 and AQ-AH 208 on improving the recovery of subendocardial contractile function (% SS) may be explained partially by a reduction in myocardial oxygen requirements as a result of bradycardia. These results suggest that specific bradycardic agents may have potential for treatment of certain types of myocardial ischemia.

Volume 238, Issue 2, pp. 422-428, 08/01/1986
Copyright © 1986 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
X. Monnet, B. Ghaleh, P. Colin, O. P. de Curzon, J.-F. Giudicelli, and A. Berdeaux
Effects of Heart Rate Reduction with Ivabradine on Exercise-Induced Myocardial Ischemia and Stunning
J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 1133 - 1139.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1986 by the American Society for Pharmacology and Experimental Therapeutics.